1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Excess burden of age-associated comorbidities among people living with HIV in British Columbia, Canada: a population-based cohort study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          As people living with HIV (PLWH) live longer, morbidity and mortality from non-AIDS comorbidities have emerged as major concerns. Our objective was to compare prevalence trends and age at diagnosis of nine chronic age-associated comorbidities between individuals living with and without HIV.

          Design and setting

          This population-based cohort study used longitudinal cohort data from all diagnosed antiretroviral-treated PLWH and 1:4 age-sex-matched HIV-negative individuals in British Columbia, Canada.

          Participants

          The study included 8031 antiretroviral-treated PLWH and 32 124 HIV-negative controls (median age 40 years, 82% men). Eligible participants were ≥19 years old and followed for ≥1 year during 2000 to 2012.

          Primary and secondary outcome measures

          The presence of non-AIDS-defining cancers, diabetes, osteoarthritis, hypertension, Alzheimer’s and/or non-HIV-related dementia, cardiovascular, kidney, liver and lung diseases were identified from provincial administrative databases. Beta regression assessed annual age-sex-standardised prevalence trends and Kruskal-Wallis tests compared the age at diagnosis of comorbidities stratified by rate of healthcare encounters.

          Results

          Across study period, the prevalence of all chronic age-associated comorbidities, except hypertension, were higher among PLWH compared with their community-based HIV-negative counterparts; as much as 10 times higher for liver diseases (25.3% vs 2.1%, p value<0.0001). On stratification by healthcare encounter rates, PLWH experienced most chronic age-associated significantly earlier than HIV-negative controls, as early as 21 years earlier for Alzheimer’s and/or dementia.

          Conclusions

          PLWH experienced higher prevalence and earlier age at diagnosis of non-AIDS comorbidities than their HIV-negative controls. These results stress the need for optimised screening for comorbidities at earlier ages among PLWH, and a comprehensive HIV care model that integrates prevention and treatment of chronic age-associated conditions. Additionally, the robust methodology developed in this study, which addresses concerns on the use of administrative health data to measure prevalence and incidence, is reproducible to other settings.

          Related collections

          Most cited references43

          • Record: found
          • Abstract: found
          • Article: not found

          The end of AIDS: HIV infection as a chronic disease.

          The success of antiretroviral therapy has led some people to now ask whether the end of AIDS is possible. For patients who are motivated to take therapy and who have access to lifelong treatment, AIDS-related illnesses are no longer the primary threat, but a new set of HIV-associated complications have emerged, resulting in a novel chronic disease that for many will span several decades of life. Treatment does not fully restore immune health; as a result, several inflammation-associated or immunodeficiency complications such as cardiovascular disease and cancer are increasing in importance. Cumulative toxic effects from exposure to antiretroviral drugs for decades can cause clinically-relevant metabolic disturbances and end-organ damage. Concerns are growing that the multimorbidity associated with HIV disease could affect healthy ageing and overwhelm some health-care systems, particularly those in resource-limited regions that have yet to develop a chronic care model fully. In view of the problems inherent in the treatment and care for patients with a chronic disease that might persist for several decades, a global effort to identify a cure is now underway. Copyright © 2013 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Premature age-related comorbidities among HIV-infected persons compared with the general population.

            Human immunodeficiency virus (HIV)-infected patients may have a greater risk of noninfectious comorbidities (NICMs) compared with the general population. We assessed the prevalence and risk factors for NICMs in a large cohort of HIV-infected adults and compared these findings with data from matched control subjects. We performed a case-control study involving antiretroviral therapy (ART)-experienced HIV-infected patients treated at Modena University, Italy, from 2002 through 2009. These patients were compared with age-, sex-, and race-matched adults (control subjects) from the general population included in the CINECA ARNO database. NICMs included cardiovascular disease, hypertension, diabetes mellitus, bone fractures, and renal failure. Polypathology (Pp) was defined as the concurrent presence of ≥2 NICMs. Logistic regression models were constructed to evaluate associated predictors of NICMs and Pp. There were 2854 patients and 8562 control subjects. The mean age was 46 years, and 37% were women. Individual NICM and Pp prevalences in each age stratum were higher among patients than among controls (all P <.001). Pp prevalence among patients aged 41-50 years was similar to that among controls aged 51-60 years (P value was not statistically significant); diabetes mellitus, cardiovascular disease, bone fractures, and renal failure were statistically independent after adjustment for sex, age, and hypertension. Logistic regression models showed that independent predictors of Pp in the overall cohort were (all P < .001) age (odds ratio [OR], 1.11), male sex (OR, 1.77), nadir CD4 cell count <200 cells/μL (OR, 4.46), and ART exposure (OR, 1.01). Specific age-related NICMs and Pp were more common among HIV-infected patients than in the general population. The prevalence of Pp in HIV-infected persons anticipated Pp prevalence observed in the general population among persons who were 10 years older, and HIV-specific cofactors (lower nadir CD4 cell count and more prolonged ART exposure) were identified as risk factors. These data support the need for earlier screening for NICMs in HIV-infected patients.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

              Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There are limited data on their use in low- and middle-income countries.
                Bookmark

                Author and article information

                Journal
                BMJ Open
                BMJ Open
                bmjopen
                bmjopen
                BMJ Open
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                2044-6055
                2021
                8 January 2021
                : 11
                : 1
                : e041734
                Affiliations
                [1 ]British Columbia Centre for Excellence in HIV/AIDS , Vancouver, British Columbia, Canada
                [2 ]The University of British Columbia Faculty of Medicine , Vancouver, British Columbia, Canada
                [3 ]VA Connecticut Health System , West Haven, Connecticut, USA
                [4 ]Yale School of Medicine , New Haven, Connecticut, USA
                [5 ]Arthritis Research Centre Of Canada , Richmond, British Columbia, Canada
                [6 ]The University of British Columbia School of Population and Public Health , Vancouver, British Columbia, Canada
                [7 ]Simon Fraser University Faculty of Health Sciences , Burnaby, British Columbia, Canada
                Author notes
                [Correspondence to ] Dr Viviane D Lima; vlima@ 123456bccfe.ca
                Author information
                http://orcid.org/0000-0002-3723-6418
                Article
                bmjopen-2020-041734
                10.1136/bmjopen-2020-041734
                7799128
                33419911
                8da875bf-0483-4d70-b6a9-92698fcb729c
                © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 16 June 2020
                : 10 December 2020
                : 18 December 2020
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100000272, National Institute for Health Research;
                Award ID: NIDA R01DA036307
                Funded by: FundRef http://dx.doi.org/10.13039/501100004726, Ministry of Health;
                Funded by: FundRef http://dx.doi.org/10.13039/501100000024, Canadian Institutes of Health Research;
                Award ID: Canada Graduate Student – Master’s Award
                Award ID: Foundation Award (#143342)
                Award ID: New Investigator Award
                Award ID: Operating Grant (#130419)
                Award ID: PJT-148595
                Funded by: FundRef http://dx.doi.org/10.13039/501100008002, Vancouver Coastal Health Research Institute;
                Funded by: FundRef http://dx.doi.org/10.13039/501100000245, Michael Smith Foundation for Health Research;
                Award ID: Scholar Award
                Funded by: FundRef http://dx.doi.org/10.13039/100011094, Public Health Agency of Canada;
                Funded by: FundRef http://dx.doi.org/10.13039/501100005247, University of British Columbia;
                Award ID: Four-Year Doctoral Fellowship
                Funded by: FundRef http://dx.doi.org/10.13039/501100002879, Canadian HIV Trials Network, Canadian Institutes of Health Research;
                Award ID: CTN 248
                Categories
                Epidemiology
                1506
                1692
                Original research
                Custom metadata
                unlocked

                Medicine
                epidemiology,hiv & aids,public health
                Medicine
                epidemiology, hiv & aids, public health

                Comments

                Comment on this article